OncoSil Medical Dividend

Dividend criteria checks 0/6

OncoSil Medical does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-10.0%

Buyback Yield

Total Shareholder Yield	-10.0%
Future Dividend Yield	0%
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend updates

No updates

Recent updates

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

Dec 04

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if OSL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OSL's dividend payments have been increasing.

Dividend Yield vs Market

OncoSil Medical Dividend Yield vs Market

How does OSL dividend yield compare to the market?
Segment	Dividend Yield
Company (OSL)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.2%
Industry Average (Life Sciences)	0.6%
Analyst forecast (OSL) (up to 3 years)	0%

Notable Dividend: Unable to evaluate OSL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OSL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate OSL's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OSL has not reported any payouts.

OncoSil Medical Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

OncoSil Medical Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.005 loss per share (vs AU$0.01 loss in FY 2023)

Peter Hall Elects Not to Join Oncosil Medical Limited's Board

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

OncoSil Medical Limited Appoints Peter Hall as Non-Executive Director

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 2.7 million.

New major risk - Market cap size

OncoSil Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 1.48 million.

New major risk - Market cap size

Oncosil Medical Limited Elects Gabrielle Liberatore as Director

New major risk - Market cap size

New major risk - Share price stability

OncoSil Medical Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.013 loss in FY 2022)

OncoSil Appoints Gabriel Liberatore to the Board

OncoSil Medical Limited Announces Appointment of Dal Cin as Chief Financial Officer

Oncosil Medical Ltd Announces Resignation of Karl Pechmann as Chief Financial Officer

Insider recently bought AU$1.2m worth of stock

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.007 loss in 1H 2022)

Oncosil Medical Limited Announces Two Key Treatment Centres Treat First Patients with Oncosil

OncoSil Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 6.09495 million.

Forecast to breakeven in 2025

Less than half of directors are independent

OncoSil Medical Limited Announces Resignation of Martin Cross as Director

OncoSil Medical Ltd Appoints Brian Leedman to the Board as a Non-Executive Director

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OncoSil Medical Limited, Annual General Meeting, Oct 25, 2022

Oncosil Medical Ltd Announces Second Patient Treated in Spain Proceeds to Successful Resection

Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky

Less than half of directors are independent

OncoSil Medical Ltd. Announces the First Commercial Treatment of the OncoSilTM Device in Europe

OncoSil Medical Limited Announces Fully-Funded Trial Approval in Germany To Increase Sales of OncoSil Device

Price target increased to AU$0.17

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation

Oncosil Medical Limited announces PanCO Clinical Study on OncoSil(TM) Published in ESMO Open

Less than half of directors are independent

Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?

Full year 2021 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in FY 2020)

OncoSil Medical Limited Provides Update on TGA Regulatory

OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans

OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years

Analysts lower revenue estimates to AU$189.0k

Price target lowered to AU$0.34

First half 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in 1H 2020)

OncoSil Medical Limited Announces Executive Appointments

We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn

OncoSil Medical Limited Appoints Nigel Lange as Chief Executive Officer

How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?

OncoSil Medical Limited Announces Executive Changes

OncoSil Medical Limited Receives Swiss Regulatory Approval

Independent Non-Executive Chairman recently bought AU$405k worth of stock

Analysts update estimates

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies